Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Is There a Clinical Benefit to Switch Hydroxyurea (HU) Drug in Sickle Cell Disease (SCD)?

Frédéric Galactéros, MDPhD, Ersi Voskaridou, Anoosha Habibi, MD PhD, Giovanna Cannas, MD, Laure Joseph, MD, Gylna Loko, MD, Mariane De Montalembert, MD PhD, Narcisse Elenga, MD PhD, Malika Benkerrou, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140265

Published: 2020

Journal Articles

Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency

Hanny Al-Samkari, MD, Rachael F. Grace, MD, Andreas Glenthoej, MD, Oliver Andres, MD, Wilma Barcellini, Frédéric Galactéros, MDPhD, Kevin H.M. Kuo, MDMSc,FRCPC, D. Mark Layton, MB BS, Marta Morado, PhD, Vip Viprakasit, Yan Dong, PhD, Feng Tai, PhD, Peter Hawkins, PhD, Sarah Gheuens, MD PhD, Chris Bowden, MD, John B. Porter, MA, MD, FRCP, FRCPath, Eduard van Beers, MD PhD

Blood (2020) 136 (Supplement 1): 30–32.

https://doi.org/10.1182/blood-2020-136598

Published: 2020

Journal Articles

Predictive Factors for Survival in Sickle Cell Disease: A Cohort Study Using Etendard Data

Laurent Savale, MD PhD, Gylna Loko, MD, François Lionnet, Bernard Maitre, Anoosha Habibi, Jocelyn Inamo, Dora Bachir, MD, Françoise Driss, Vincent Audard, MDPhD, Etienne Audureau, Marc Humbert, Gerald Simonneau, Frédéric Galactéros, MDPhD, Florence Parent, Pablo Bartolucci, MD PhD

Blood (2018) 132 (Supplement 1): 7.

https://doi.org/10.1182/blood-2018-99-113767

Published: 2018

Journal Articles

Sustainability of Hematological and Clinical Benefits to HU Administration in the Prevention of Sickle-Cell Vaso-Occlusive Crises in Routine Practice

Ersi Voskaridou, MD, Lena Oevermann, MD, Corinne Armari-Alla, MD, Uwe Kordes, MD MRCP, Frédéric Galactéros, MDPhD, Malika Benkerrou, MD, Isabelle Thuret, MD, Dominique Steschenko, MD

Blood (2018) 132 (Supplement 1): 855.

https://doi.org/10.1182/blood-2018-99-116040

Published: 2018

Journal Articles

Management of Infections in SCD Patients Treated with HU in the Framework of Escort HU

Frédéric Galactéros, MDPhD, Malika Benkerrou, MD, Mariane De Montalembert, MD PhD, Jean-Antoine Ribeil, MD, Corinne Pondarré, MD PhD, Jean Benoît Arlet, MD, Uwe Kordes, MD MRCP, Regine Grosse, MD, Valentine Brousse, MD, Lena Oevermann, MD, Stephan Lobitz, MD

Blood (2017) 130 (Supplement 1): 3543.

https://doi.org/10.1182/blood.V130.Suppl_1.3543.3543

Published: 2017

Journal Articles

Management of Renal Dysfunctions in Escort-HU Study

Pablo Bartolucci, MD PhD, Gylna Loko, MD, Corinne Charneau, MD, Jean-Antoine Ribeil, MD, Nathalie Lemonne, MD, Stephan Lobitz, MD, Malika Benkerrou, MD, Frederic Galacteros, MDPhD

Blood (2017) 130 (Supplement 1): 3528.

https://doi.org/10.1182/blood.V130.Suppl_1.3528.3528

Published: 2017

Journal Articles

A New Tool for HbF Quantification Demonstrates That Hydroxyurea Decreases Mostly RBCs Containing Very Low Amounts of HbF

Rakotoson Marie Georgine, Marie Cambot, Gwellaouen Bodivit, Gaetana Di Liberto, PhD, Philippe Chadebech, Nicolas Hebert, Benoit Vingert, PhD, Anoosha Habibi, MD, Sadaf Pakdaman, Alicia Jouard, France Pirenne, MD PhD, Frédéric Galactéros, MDPhD, Pablo Bartolucci, MD PhD

Blood (2017) 130 (Supplement 1): 3527.

https://doi.org/10.1182/blood.V130.Suppl_1.3527.3527

Published: 2017

Journal Articles

Outcome of Severe Vaso Occlusive Crisis in Sickle Cell Disease Adults Admitted to Referral Centers in Africa and Europe. Preliminary Results from the Presev 2 Study

Dapa Diallo, Prof, Mehdi Khellaf, Gonzalo De Luna, Sandrine Dautheville, Louis Affo, Stephanie Ngo, MD, Tatiana besse-Hammer, Yvon Segbena, jean Benoit Arlet, François Lionnet, Sylvain le-Jeune, Anoosha Habibi, MD, Bertrand Godeau, Frédéric Galactéros, MDPhD, Pablo Bartolucci, MD PhD

Blood (2017) 130 (Supplement 1): 3529.

https://doi.org/10.1182/blood.V130.Suppl_1.3529.3529

Published: 2017

Journal Articles

Management of Male Fertility in Sickle Cell Disease before and after Hydroxycarbamide

Anoosha Habibi, MD, Elena Foïs, MD, Giovanna Cannas, MD, Jean-Antoine Ribeil, MD, Pierre Cougoul, MD, Emmanuelle Bernit, MD, Pablo Bartolucci, MD PhD, Frederic Galacteros, MDPhD

Blood (2017) 130 (Supplement 1): 2260.

https://doi.org/10.1182/blood.V130.Suppl_1.2260.2260

Published: 2017

Journal Articles

Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency

Blood (2017) 130 (Supplement 1): 2194.

https://doi.org/10.1182/blood.V130.Suppl_1.2194.2194

Published: 2017

Journal Articles

Off-Label Prescription of Hydroxycarbamide (Hydroxyurea, HU) for Severe Anemia: Preliminary Results from European Non-Interventional, Multicentric, Prospective Escort-HU Study

Mariane De Montalembert, MD PhD, Gylna Loko, MD, Jerome Clouzeau, MD, Valentine Brousse, MD, Frederic Galacteros, MDPhD, Corinne Charneau, MD, Marie Belloy, MD, Malika Benkerrou, MD

Blood (2017) 130 (Supplement 1): 758.

https://doi.org/10.1182/blood.V130.Suppl_1.758.758

Published: 2017

Journal Articles

Prospective Controlled Trial on Endurance Exercise Training in Adult Sickle Cell Disease Patients

Barnabas Gellen, Laurent Messonnier, Angele Merlet, Etienne Audureau, Thomas Rupp, Sandrine Peyrot, Cyril Martin, PhD, Jean-Antoine Ribeil, MD PhD, jean Benoit Arlet, Frédéric Galactéros, MDPhD, Leonard Feasson, Pablo Bartolucci, MD PhD

Blood (2017) 130 (Supplement 1): 991.

https://doi.org/10.1182/blood.V130.Suppl_1.991.991

Published: 2017

NARROW

Is There a Clinical Benefit to Switch Hydroxyurea (HU) Drug in Sickle Cell Disease (SCD)?

Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency

Predictive Factors for Survival in Sickle Cell Disease: A Cohort Study Using Etendard Data

Sustainability of Hematological and Clinical Benefits to HU Administration in the Prevention of Sickle-Cell Vaso-Occlusive Crises in Routine Practice

Management of Infections in SCD Patients Treated with HU in the Framework of Escort HU

Management of Renal Dysfunctions in Escort-HU Study

A New Tool for HbF Quantification Demonstrates That Hydroxyurea Decreases Mostly RBCs Containing Very Low Amounts of HbF

Outcome of Severe Vaso Occlusive Crisis in Sickle Cell Disease Adults Admitted to Referral Centers in Africa and Europe. Preliminary Results from the Presev 2 Study

Management of Male Fertility in Sickle Cell Disease before and after Hydroxycarbamide

Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency

Off-Label Prescription of Hydroxycarbamide (Hydroxyurea, HU) for Severe Anemia: Preliminary Results from European Non-Interventional, Multicentric, Prospective Escort-HU Study

Prospective Controlled Trial on Endurance Exercise Training in Adult Sickle Cell Disease Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only